---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-003385"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-09-26T23:59:59+00:00"
generated_at: "2026-05-17T05:37:23.940320+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Silexion Therapeutics enters ATM equity facility for up to $13.17M via H.C. Wainwright

## Summary
- At-the-market offering agreement with H.C. Wainwright to sell up to $13.17M of ordinary shares.
- Wainwright to receive 3% commission on gross proceeds; sales may occur via Nasdaq Capital Market.
- Offering terminates upon sale of all shares or earlier termination by either party.
- Company not obligated to sell any shares; sales subject to effectiveness of registration statement.

## SEC filing metadata
- accession: 0001178913-25-003385
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003385/0001178913-25-003385-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003385/zk2533809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-003385
- JSON: https://secwatch.observer/filing/0001178913-25-003385.json
- Plain text: https://secwatch.observer/filing/0001178913-25-003385.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.